Patent · US Active

EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis

US9789213B2 · kind B2 · utility

0Cited by
1References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 15, 2013
Grant dateOct 17, 2017
Priority date
Expiry dateMar 15, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Polypeptides that target and/or bind to EGFL7 or its receptor and thereby reduce EGFL7 pro-angiogenic activity are provided. In this way, the polypeptides are, in an aspect, useful in the treatment of diseases, disorders, or conditions that involve pathological angiogenesis, such as, for example, cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.